Assembly Biosciences Inc./$ASMB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Ticker
$ASMB
Sector
Primary listing
Employees
73
Headquarters
Website
ASMB Metrics
BasicAdvanced
$415M
-
-$5.56
0.65
-
Price and volume
Market cap
$415M
Beta
0.65
52-week high
$26.77
52-week low
$7.75
Average daily volume
92K
Financial strength
Current ratio
1.638
Quick ratio
1.586
Long term debt to equity
12.989
Total debt to equity
15.934
Profitability
EBITDA (TTM)
-43.392
Gross margin (TTM)
-76.77%
Net profit margin (TTM)
-117.20%
Operating margin (TTM)
-130.91%
Effective tax rate (TTM)
0.19%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
-27.74%
Return on equity (TTM)
-147.64%
Valuation
Price to revenue (TTM)
5.622
Price to book
11.3
Price to tangible book (TTM)
11.3
Price to free cash flow (TTM)
-3.347
Free cash flow yield (TTM)
-29.88%
Free cash flow per share (TTM)
-7.963
Growth
Revenue change (TTM)
54.77%
Earnings per share change (TTM)
-36.58%
3-year revenue growth (CAGR)
74.53%
3-year earnings per share growth (CAGR)
-44.53%
10-year earnings per share growth (CAGR)
-16.03%
Bulls say / Bears say
Assembly secured a $20.1 million equity investment plus $10 million in accelerated funding from Gilead, extending its cash runway into mid-2026 and bolstering financial stability through key data catalysts(Barron's).
Collaboration revenue with Gilead rose to $9.4 million in Q1 2025 from $5.8 million a year earlier, reflecting increased non-dilutive funding to support R&D programs(SEC 10-Q).
Multiple key clinical readouts are expected throughout 2025, including efficacy, safety and PK data from the ABI-4334 Phase 1b 400 mg cohort in H1 2025 and interim Phase 1b data for ABI-5366 and ABI-1179 in fall 2025, underscoring robust pipeline momentum(SEC 10-K Exhibit 99.1)
Cash, cash equivalents and marketable securities declined from $112.1 million at year-end 2024 to $91.0 million as of March 31, 2025, implying a $21.1 million quarterly cash burn that may pressure resources ahead of key pipeline milestones(GlobeNewswire).
Research and development expenses rose 25% year-over-year to $14.9 million in Q1 2025, further accelerating the company’s burn rate amid pre-commercial stage programs(GlobeNewswire).
All of Assembly Bio’s investigational candidates remain unapproved, with safety and efficacy yet to be established, exposing the company to clinical failure risk before generating any product revenue(GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 25 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Assembly Biosciences Inc. stock?
Assembly Biosciences Inc. (ASMB) has a market cap of $415M as of August 23, 2025.
What is the P/E ratio for Assembly Biosciences Inc. stock?
The price to earnings (P/E) ratio for Assembly Biosciences Inc. (ASMB) stock is 0 as of August 23, 2025.
Does Assembly Biosciences Inc. stock pay dividends?
No, Assembly Biosciences Inc. (ASMB) stock does not pay dividends to its shareholders as of August 23, 2025.
When is the next Assembly Biosciences Inc. dividend payment date?
Assembly Biosciences Inc. (ASMB) stock does not pay dividends to its shareholders.
What is the beta indicator for Assembly Biosciences Inc.?
Assembly Biosciences Inc. (ASMB) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.